Biotech Industry Victorious in Appeals Ruling; High Court Likely to Weigh In

Washington Drug Letter
In a victory for the biotechnology industry, the U.S. Court of Appeals for the Federal Circuit ruled 2–1 to reaffirm its earlier ruling that Myriad Genetics can patent genes related to its breast and ovarian cancer screening system.

To View This Article:


Buy This Article Now

Add this article to your cart for $25.00